{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T20:04:00Z","timestamp":1767211440120},"reference-count":10,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina de Familia. SEMERGEN"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.semerg.2019.06.005","type":"journal-article","created":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T07:54:43Z","timestamp":1563782083000},"page":"e51-e52","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tratamiento de la elevaci\u00f3n de prolactina por psicof\u00e1rmacos en personas con discapacidad intelectual"],"prefix":"10.1016","volume":"45","author":[{"given":"E.","family":"Gonz\u00e1lez-Pablos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Mart\u00edn-Lorenzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Valles-de la Calle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Paulino-Matos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semerg.2019.06.005_bib0055","first-page":"e1","article-title":"Elevaci\u00f3n de prolactina en personas con discapacidad intelectual con tratamiento psicofarmacol\u00f3gico","volume":"45","author":"Gonz\u00e1lez-Pablos","year":"2019","journal-title":"Semergen"},{"key":"10.1016\/j.semerg.2019.06.005_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.semerg.2019.02.008","article-title":"Aripiprazol en el tratamiento de pacientes con discapacidad intelectual y elevaci\u00f3n de los niveles de prolactina","author":"Muquebil Ali Al Shaban","year":"2019","journal-title":"Semergen"},{"key":"10.1016\/j.semerg.2019.06.005_bib0065","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.endonu.2012.11.005","article-title":"Gu\u00eda cl\u00ednica de diagn\u00f3stico y tratamiento del prolactinoma y la hiperprolactinemia","volume":"60","author":"Halperin Rabinovich","year":"2013","journal-title":"Endocrinol Nutr"},{"key":"10.1016\/j.semerg.2019.06.005_bib0070","first-page":"251","article-title":"Consenso sobre la salud f\u00edsica del paciente con esquizofrenia de las Sociedades Espa\u00f1olas de Psiquiatr\u00eda y Psiquiatr\u00eda Biol\u00f3gica","volume":"36","author":"S\u00e1iz Ruiz","year":"2008","journal-title":"Actas Esp Psiquatr"},{"key":"10.1016\/j.semerg.2019.06.005_bib0075","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.semerg.2019.06.005_bib0080","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.rpsm.2011.07.003","article-title":"Recomendaciones para el cambio de antipsic\u00f3ticos. Posicionamiento de las Sociedad Espa\u00f1ola de psiquiatr\u00eda y de la sociedad Espa\u00f1ola de Psiquiatr\u00eda Biologica","volume":"4","author":"Bernardo","year":"2011","journal-title":"Rev Psiquiatr Salud Ment (Barc.)"},{"key":"10.1016\/j.semerg.2019.06.005_bib0085","first-page":"27","article-title":"Hiperprolactinemia y tratamiento antipsic\u00f3tico. Manifestaciones cl\u00ednicas y manejo","volume":"20","author":"Rubio-Abadal","year":"2013","journal-title":"Psiq Biol"},{"key":"10.1016\/j.semerg.2019.06.005_bib0090","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.rpsm.2015.11.003","article-title":"Consenso espa\u00f1ol sobre los riesgos y detecci\u00f3n de la hiperprolactinemia iatrog\u00e9nica por antipsic\u00f3ticos","volume":"9","author":"Montejo","year":"2016","journal-title":"Rev Psiquiatr Salud Ment (Bar)"},{"key":"10.1016\/j.semerg.2019.06.005_bib0095","first-page":"13","article-title":"Causas y manejo de la hiperprolactinemia por antipsic\u00f3ticos","volume":"22","author":"Murru","year":"2015","journal-title":"Psiq Biol"},{"key":"10.1016\/j.semerg.2019.06.005_bib0100","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/j.2051-5545.2009.tb00248.x","article-title":"Gu\u00eda internacional para la prescripci\u00f3n de psicof\u00e1rmacos en el tratamiento de problemas de conducta de adultos con discapacidad intelectual","author":"Deb","year":"2009","journal-title":"World Psychiatry (Ed Esp)"}],"container-title":["Medicina de Familia. SEMERGEN"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359319301972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359319301972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T10:43:09Z","timestamp":1575024189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1138359319301972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S1138359319301972"],"URL":"https:\/\/doi.org\/10.1016\/j.semerg.2019.06.005","relation":{},"ISSN":["1138-3593"],"issn-type":[{"value":"1138-3593","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tratamiento de la elevaci\u00f3n de prolactina por psicof\u00e1rmacos en personas con discapacidad intelectual","name":"articletitle","label":"Article Title"},{"value":"Medicina de Familia. SEMERGEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semerg.2019.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Sociedad Espa\u00f1ola de M\u00e9dicos de Atenci\u00f3n Primaria (SEMERGEN). Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}